Acquisition of Own Shares

Mechelen, Belgium; 01 September 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") announces that between August 24, 2026 and August 28, 2026 it has repurchased 127,796 Lakefront shares via a discretionary mandate to an independent financial intermediary, as follows: Date of purchase Market/MTF Number of shares Average price paid (€) Total (€) Lowest price paid (€) Highest price paid (€) 24/08/2026 XAMS 21,820 24.56 535,857.74 24.36 24.64 24/08/2026 TQEX 450 24.55 11,045.43 24.54 24.60 24/08/2026 CEUX 328 24.58 8,062.37 24.54 24.64 24/08/2026 AQEU 1,333 24.61 32,811.40 24.58 24.66 25/08/2026 XAMS 21,058 25.29 532,464.16 24.94 25.52 25/08/2026 TQEX 698 25.25 17,623.66 25.00 25.36 25/08/2026 CEUX 600 25.28 15,165.48 25.24 25.34 25/08/2026 AQEU 313 25.29 7,914.33 25.26 25.34 26/08/2026 XAMS 22,968 25.45 584,632.07 25.08 25.64 26/08/2026 TQEX 599 25.45 15,241.91 25.30 25.64 26/08/2026 CEUX 1,703 25.47 43,377.62 25.24 25.66 26/08/2026 AQEU 539 25.50 13,744.72 25.32 25.60 27/08/2026 XAMS 21,382 25.27 540,406.53 25.06 25.36 27/08/2026 TQEX 904 25.27 22,843.72 25.20 25.32 27/08/2026 CEUX 2,342 25.24 59,114.89 25.12 25.36 27/08/2026 AQEU 440 25.23 11,100.50 25.12 25.34 28/08/2026 XAMS 25,694 25.29 649,927.16 25.00 25.50 28/08/2026 TQEX 1,110 25.40 28,194.11 25.36 25.46 28/08/2026 CEUX 3,363 25.38 85,342.18 25.08 25.46 28/08/2026 AQEU 152 25.26 3,840.17 25.14 25.46 Total   127,796 25.19 3,218,710.15 24.36 25.66 As of market close on 28 August 2026, Lakefront holds 1,161,324 of its own ordinary shares. About Lakefront Biotherapeutics Lakefront Biotherapeutics is a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need.

GlobeNewsWire • Sep 1, 2026

Lakefront Receives Transparency Notification from Bank of America

Mechelen, Belgium; August 24, 2026, 22.01 CET; regulated information – Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) received a transparency notification from Bank of America.

GlobeNewsWire • Aug 24, 2026

U.S. FDA Grants Orphan Drug Designation to Gamgertamig for the Treatment of Pemphigus

Mechelen, Belgium; 24 August 2026, 22.01 CET; regulated information – Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to gamgertamig for the treatment of pemphigus. Gamgertamig was previously granted both Fast Track and Orphan Drug Designation by the U.S. FDA for the treatment of autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP).

GlobeNewsWire • Aug 24, 2026

Lakefront Announces Paulo Fontoura has Resigned from its Board following his Appointment as Global Head of R&D at Sanofi

Mechelen, Belgium; July 13, 2026, 22:01 CET; Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced that following his appointment as Executive Vice President, Global Head of Research & Development Pharma at Sanofi SA, Dr. Paulo Fontoura has tendered his resignation from the Board of Directors.

GlobeNewsWire • Jul 13, 2026

Lakefront Receives Transparency Notification from Madison Avenue Partners

Mechelen, Belgium; June 29, 2026, 22.01 CET; regulated information – Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) received a transparency notification from Madison Avenue Partners.

GlobeNewsWire • Jun 29, 2026

Lakefront Announces Initiation of €50 Million Stock Repurchase Program

Mechelen, Belgium ; June 9, 2026, 22:01 CET; regulated information – Lakefront Bio therapeutics NV (Euronext & NASDAQ: LKFT) today announced the launch of a share repurchase program (the “Program”), under which the Company may repurchase ordinary shares for an aggregate amount of up to €50 Million. Repurchases under the Program may be made no later than December 31, 2026. The Program is entered into with Morgan Stanley & Co International PLC.

GlobeNewsWire • Jun 9, 2026

Lakefront Appoints Eric Hedrick, MD, as Chief Medical Officer

Mechelen, Belgium ; June 8, 2026, 22:01 CET; Lakefront Bio therapeutics NV (Euronext & NASDAQ: LKFT) today announced that Eric Hedrick, MD has been appointed Chief Medical Officer. This expanded leadership role supports the Company's strategic transformation following its acquisition of Ouro Medicines operational assets announced on June 4, 2026. 1 Eric will report to Henry Gosebruch, CEO and join the Company's Management Committee.

GlobeNewsWire • Jun 8, 2026